Allele-specific RNA interference prevents neuropathy in Charcot-Marie-Tooth disease type 2D mouse models. by Morelli, Kathryn H et al.
Thomas Jefferson University 
Jefferson Digital Commons 
Department of Biochemistry and Molecular 
Biology Faculty Papers 
Department of Biochemistry and Molecular 
Biology 
12-2-2019 
Allele-specific RNA interference prevents neuropathy in Charcot-
Marie-Tooth disease type 2D mouse models. 
Kathryn H Morelli 
Jackson Laboratory & University of Maine 
Laurie B Griffin 
University of Michigan 
Nettie K Pyne 
Center for Gene Therapy, Research Institute at Nationwide Children's Hospital 
Lindsay M Wallace 
Center for Gene Therapy, Research Institute at Nationwide Children's Hospital 
Allison M Fowler 
Center for Gene Therapy, Research Institute at Nationwide Children's Hospital 
See next page for additional authors 
Follow this and additional works at: https://jdc.jefferson.edu/bmpfp 
 Part of the Medical Biochemistry Commons 
Let us know how access to this document benefits you 
Recommended Citation 
Morelli, Kathryn H; Griffin, Laurie B; Pyne, Nettie K; Wallace, Lindsay M; Fowler, Allison M; 
Oprescu, St phanie N; T k se, Ryuichi; Wei, Na; Meyer-Schuman, Rebecca; Mellacheruvu, 
Dattatreya; Kitzman, Jacob O; Kocen, Samuel G; Hines, Timothy J; Spaulding, Emily L; Lupski, 
James R; Nesvizhskii, Alexey; Mancias, Pedro; Butler, Ian J; Yang, Xiang-Lei; Hou, Ya-Ming; 
Antonellis, Anthony; Harper, Scott Q; and Burgess, Robert W, "Allele-specific RNA interference 
prevents neuropathy in Charcot-Marie-Tooth disease type 2D mouse models." (2019). 
Department of Biochemistry and Molecular Biology Faculty Papers. Paper 163. 
https://jdc.jefferson.edu/bmpfp/163 
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital 
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is 
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections 
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested 
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been 
accepted for inclusion in Department of Biochemistry and Molecular Biology Faculty Papers by an authorized 
administrator of the Jefferson Digital Commons. For more information, please contact: 
JeffersonDigitalCommons@jefferson.edu. 
Authors 
Kathryn H Morelli, Laurie B Griffin, Nettie K Pyne, Lindsay M Wallace, Allison M Fowler, Stephanie N 
Oprescu, Ryuichi Takase, Na Wei, Rebecca Meyer-Schuman, Dattatreya Mellacheruvu, Jacob O Kitzman, 
Samuel G Kocen, Timothy J Hines, Emily L Spaulding, James R Lupski, Alexey Nesvizhskii, Pedro Mancias, 
Ian J Butler, Xiang-Lei Yang, Ya-Ming Hou, Anthony Antonellis, Scott Q Harper, and Robert W Burgess 
This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/bmpfp/163 
Allele-specific RNA interference prevents
neuropathy in Charcot-Marie-Tooth disease type
2D mouse models
Kathryn H. Morelli, … , Scott Q. Harper, Robert W. Burgess
J Clin Invest. 2019;129(12):5568-5583. https://doi.org/10.1172/JCI130600.
  
Gene therapy approaches are being deployed to treat recessive genetic disorders by
restoring the expression of mutated genes. However, the feasibility of these approaches for
dominantly inherited diseases — where treatment may require reduction in the expression
of a toxic mutant protein resulting from a gain-of-function allele — is unclear. Here we show
the efficacy of allele-specific RNAi as a potential therapy for Charcot-Marie-Tooth disease
type 2D (CMT2D), caused by dominant mutations in glycyl-tRNA synthetase (GARS). A de
novo mutation in GARS was identified in a patient with a severe peripheral neuropathy, and
a mouse model precisely recreating the mutation was produced. These mice developed a
neuropathy by 3–4 weeks of age, validating the pathogenicity of the mutation. RNAi
sequences targeting mutant GARS mRNA, but not wild-type, were optimized and then
packaged into AAV9 for in vivo delivery. This almost completely prevented the neuropathy
in mice treated at birth. Delaying treatment until after disease onset showed modest benefit,
though this effect decreased the longer treatment was delayed. These outcomes were
reproduced in a second mouse model of CMT2D using a vector specifically targeting that
allele. The effects were dose dependent, and persisted for at least 1 year. Our findings
demonstrate the feasibility of AAV9-mediated allele-specific knockdown and provide proof
of concept for gene therapy approaches for dominant neuromuscular diseases.
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Introduction
Personalized medicine seeks to provide optimized treatments 
for individuals based on the molecular characteristics of their 
specific disease. For example, cancer treatments are custom-
ized to the genetics of the patient and the tumor (1, 2). However, 
developing personalized treatments for rare Mendelian disor-
ders is challenging, and only about 5% of the more than 6800 
recognized rare diseases have approved therapies (https://
www.genome.gov/2 7 5 3 1963/faq-about-rare- diseases/). 
Often, even when a disease gene is defined, the pathological 
impacts of specific genetic lesions may be uncertain or vari-
able. In such cases, animal models recapitulating molecular 
lesions offer a means for validating the causality of new human 
mutations, and can serve as surrogates in preclinical therapeu-
tic development (3, 4).
Gene therapy is a potentially powerful approach for treating 
rare genetic disorders, as it can precisely address the primary 
cause of these conditions (5). Gene therapy approaches are now 
in the clinic to treat recessive loss-of-function conditions by 
restoring the expression of the mutated genes (6, 7). However, 
the feasibility of gene silencing therapy to treat dominantly 
inherited, monoallelic mutations — where treatment may 
require reduction in the expression of a toxic mutant protein 
resulting from a gain-of-function allele — is unclear. To date, 
Clinical Trials.gov lists only 2 phase I/II studies designed to 
test the safety of vector-expressed inhibitory RNAs in humans, 
and both were indicated for suppressing chronic hepatitis virus 
infection (NCT01899092 and NCT02315638). Thus, RNAi-
based therapy is still an emerging field.
Here, we combine precision models of a dominant inherited 
neuropathy — Charcot-Marie-Tooth disease type 2D (MIM 
#601472), caused by mutations in glycyl-tRNA synthetase (GARS) 
(MIM #600287) — with allele-specific knockdown by viral vector– 
delivered gene therapy to demonstrate the effectiveness of this 
strategy. We designed our treatment for a single patient, but this 
sets an important precedent, as 90% of inherited peripheral 
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after a pregnancy complicated by hypertension. She required 
oxygen supplementation and had mild neonatal jaundice, but 
was discharged after 5 days. Newborn screening was normal, 
and motor development was probably normal at first, with the 
ability to reach for objects at 4 months and stand with support at 
8 months. There was no history of seizures, and cognitive devel-
opment was uncompromised.
Muscle biopsy at 15 months was indicative of neurogenic 
changes consistent with motor neuronopathy or neuropathy. This 
included marked atrophy of type I and II fibers with isolated, clus-
tered, and fascicles of hypertrophied type I myofibers. There was 
no evidence of myofiber necrosis, degeneration, or regeneration, 
nor of dystrophic or inflammatory myopathy. Electromyography 
and nerve conduction studies were consistent with motor neuron 
disease: motor nerve conduction velocities were reduced (26 m/s 
upper and 15 m/s lower), while sensory examination revealed no 
deficits, including sensory nerve conduction (2.0 milliseconds 
latency and 46 μV at her wrist). At 20 months, MRI of the brain 
and cervical spinal cord were normal, as was an analysis of the 
cerebrospinal fluid. She did not display evidence of further decline 
and did not regress in any areas. Indeed, she seemed slightly 
stronger overall with no problems swallowing or drinking. Cranial 
nerves were intact and there was no evidence of tongue fascicu-
lation. However, motor examination revealed decreased muscle 
mass and tone, axillary slippage, flaccid lower limbs, and high-
arched feet. She could still sit independently using her upper limbs 
for support, and displayed head lag and an inability to stand on her 
own. A diagnosis of neuronopathy was suspected; however, there 
was no reported family history of this phenotype, and the patient’s 
nonidentical twin brother was unaffected.
A recessive or dominant de novo inheritance pattern was pre-
dicted. Patient DNA was extracted and subjected to both targeted 
and unbiased screening strategies. This revealed 2 full-length, 
WT copies of the SMN1 gene and 1 copy of SMN2, ruling out spi-
nal muscular atrophy types I through III. Furthermore, targeted 
analysis did not reveal mutations in IGHMBP2 or UBE1, ruling 
out recessive, distal spinal muscular atrophy and X-linked spinal 
muscular atrophy type II, respectively. Whole-exome sequencing 
analysis revealed that the patient is heterozygous for a 12-nucle-
otide deletion in exon 8 of the glycyl-tRNA synthetase (GARS) 
gene (c.894_905del; GenBank NM_002047.2). This mutation 
resulted in the deletion of 4 amino acids in the GARS protein 
(p.Glu299_Gln302del; NP_002038.2), hereafter referred to as 
ΔETAQ. No other potentially pathogenic variant was identified 
at another locus that could potentially explain the severity of 
the neuropathy by a dual molecular diagnosis (24). Neither par-
ent carries the identified GARS mutation, nor does the patient’s 
twin brother, indicating a de novo mutation. GARS functions to 
ligate glycine onto cognate tRNA molecules. The ΔETAQ GARS 
mutation results in the deletion of 4 amino acid residues that 
are conserved from human to bacteria and that reside within the 
glycine-binding pocket (Figure 1A and ref. 25).
To determine whether the ΔETAQ GARS mutation affects 
mRNA expression or stability, we performed RNA-Seq in patient 
primary dermal fibroblasts. These analyses revealed an even dis-
tribution of WT (53.7%) and ΔETAQ (46.3%) RNA-Seq reads, indi-
cating that ΔETAQ GARS does not dramatically affect transcript 
neuropathies — as well as the majority of familial amyotrophic 
lateral sclerosis cases — are inherited in an autosomal dominant 
manner (8, 9).
Charcot-Marie-Tooth disease type 2D (CMT2D) is a progres-
sive, inherited axonal neuropathy caused by dominant muta-
tions in GARS, encoding glycyl-tRNA synthetase (10). Muta-
tions in GARS also cause a purely motor neuropathy, clinically 
designated as distal spinal muscular atrophy type V, but this is 
allelic with CMT2D (11). There is no treatment for CMT2D or 
any other form of inherited peripheral neuropathy. To date, at 
least 19 individual mutations in GARS have been identified in 
patients with CMT2D (12), all of which result in single–amino 
acid changes in different functional domains of GARS (10, 
13–16). However, the mechanisms through which mutant forms 
of GARS cause axon degeneration remain unclear, limiting the 
development of a small-molecule therapy.
Most disease-associated GARS variants cause impaired enzy-
matic activity in the charging of glycine onto tRNAGly in vitro and/
or decreased cellular viability in yeast complementation assays, 
consistent with a loss-of-function effect (17, 18). However, protein- 
null alleles in mice and humans do not cause dominant neurop-
athy, ruling out haploinsufficiency and suggesting a dominant- 
negative (antimorph) mechanism (19–22). Furthermore, trans-
genic overexpression of wild-type (WT) GARS does not rescue 
the neuropathy in mouse models, suggesting that mutant forms of 
GARS adopt a toxic gain-of-function (neomorph) activity that the 
WT protein cannot outcompete (20). One proposed neomorphic 
mechanism involves the abnormal binding of mutant GARS to 
the developmental receptor neuropilin-1 (NRP1). This interaction 
competes with the normal binding of vascular endothelial growth 
factor (VEGF), an endogenous ligand of NRP1 (23).
Together, these data support a model in which suppression 
of the mutant allele of GARS should be of therapeutic benefit, 
whereas enhancing normal GARS function is ineffective. To 
achieve this suppression, we developed a gene therapy strat-
egy to reduce the levels of mutant Gars transcripts through 
allele-specific RNAi, triggered through the delivery of mutant 
Gars–targeted artificial microRNA (miRNA) expression cassettes 
packaged within self-complementary adeno-associated viral 
vectors, serotype 9 (scAAV9).
Results
We sought to demonstrate the therapeutic efficacy of a patient- 
specific RNAi-based gene therapy in a “humanized” mouse model 
expressing a patient-specific GARS mutation introduced into 
the mouse Gars gene. A 13-month-old female presented with 
impaired motor skills and regressing motor milestones involv-
ing both upper and lower extremities. She was able to sit inde-
pendently, but used her arms to stabilize herself in a sitting posi-
tion (tripod sitting). Increased lumbar lordosis was also noted at 
first examination. Dysmorphic features were noted, likely due 
to generalized muscle atrophy. Extraocular muscle function was 
normal. Deep tendon reflexes were difficult to obtain or absent, 
and she showed general, marked decreases in muscle tone, head 
lag, axillary slippage, mild tongue atrophy, ligamentous laxity 
in the hands and feet, and excessive retraction of the chest wall. 
The patient was delivered by C-section at 37 weeks gestation 
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GARS (23), the V5 signal associated with ΔETAQ GARS was much 
weaker, although stronger than that of WT GARS, which showed 
no V5 signal (Figure 1D). No interaction between ΔETAQ GARS 
and NRP1 was detected in unbiased mass spectrometry analyses 
of proteins immunoprecipitated from mouse neuro blastoma 
(MN1) cells expressing FLAG-tagged WT or V5-tagged ΔETAQ 
GARS (Supplemental Figure 2). In sum, ΔETAQ showed a 
severe defect in aminoacylation activity and, at best, a slight 
aberrant interaction with NRP1.
To definitively validate the pathogenicity of ΔETAQ GARS in 
vivo, we engineered a mouse model in which the mutation was 
introduced into the mouse Gars gene (GarsΔETAQ/+) (see Methods). 
For subsequent preclinical studies, GarsΔETAQ/+ mice were crossed 
to GarshuEx8/huEx8, a second mouse model engineered to harbor 
a “humanized” WT GARS exon 8 replacement in the mouse 
gene. The 50 amino acids encoded by exon 8 are 100% identi-
cal between mouse and human, although there are silent single- 
nucleotide differences between the mouse and human Gars/GARS 
exon 8 that could affect allele specificity of gene silencing. Our 
attempts to introduce these additional human changes when engi-
neering the ΔETAQ allele were unsuccessful, and only the 12-bp 
deletion was incorporated.
This breeding produced a cohort of GarsΔETAQ /huEx8 mice with 
GarshuEx8/+ littermate controls. Reverse transcriptase PCR using 
cDNA isolated from sciatic nerve of heterozygous mice revealed 
coexpression of ΔETAQ and WT Gars (Supplemental Figure 3A). 
A Western blot analysis of brain homogenates using a poly clonal 
anti-GARS antibody confirmed that ΔETAQ Gars did not alter 
GARS protein levels, suggesting that a stable transcript and pro-
tein products are produced from the ΔETAQ allele, as in patient 
fibroblasts (Supplemental Figure 3B).
At 12 weeks of age, GarsΔETAQ/huEx8 and GarshuEx8/+ littermates 
were evaluated for features of primary neuropathy, as observed 
in other mouse models of CMT2D (22, 26). GarsΔETAQ/huEx8 mice 
displayed overt neuromuscular dysfunction and a reduction in 
levels (Supplemental Figure 1A; supplemental material available 
online with this article; https://doi.org/10.1172/JCI130600DS1). 
To examine GARS protein levels, we performed Western blot 
analysis on whole-cell lysates from patient cells compared with a 
control primary dermal fibroblast cell line (i.e., bearing no GARS 
mutations). These experiments did not reveal an observable dif-
ference in total GARS protein levels in the affected fibroblasts 
compared with the control cell line (Supplemental Figure 1B). We 
next performed aminoacylation assays and yeast complemen-
tation tests to assess whether ΔETAQ GARS affects the primary 
activity of the enzyme. Analysis of the initial rate of aminoacy-
lation as a function of the tRNA substrate concentration showed 
that ΔETAQ GARS retained less than 0.01% aminoacylation 
activity (Figure 1B and Supplemental Table 1) compared with WT 
GARS. In parallel, we tested the previously described mouse allele 
P234KY (P278KY in the mouse, where 234 is numbered without 
the 44–amino acid mitochondrial targeting sequence), given its 
nearby location in the protein (Figure 1A and ref. 22). Although 
the P234KY allele showed activity in assays with saturating tRNA 
and glycine substrate concentrations (22), a reevaluation of kinetic 
properties under Michaelis-Menten conditions showed a marked 
decrease in enzyme activity (Figure 1B and Supplemental Table 1). 
The reduced function of the ΔETAQ allele was further supported 
by the failure of this mutant protein to complement ablated cel-
lular growth associated with deletion of the yeast ortholog GRS1 
(Figure 1C). Data from this latter assay also support the loss-of-
function effect associated with P278KY Gars (Figure 1C), and are 
consistent with the failure of the mouse P278KY allele to comple-
ment an RNA-null allele of Gars (22).
Neuropathy-associated GARS mutations bind inappropriately 
to NRP1 (23). To test for binding between ΔETAQ GARS and NRP1, 
we expressed V5-tagged WT, P234KY, and ΔETAQ GARS in the 
mouse NSC-34 cells. After immunoprecipitation with an anti-NRP1 
antibody, Western blots were performed using an anti-V5 anti-
body. In contrast to the reported strong association with P234KY 
Figure 1. In vitro characterization of ΔETAQ mutation. (A) 
The position and evolutionary conservation of the ΔETAQ 
(red) and P234KY (green) GARS mutations. (B) Initial 
aminoacylation rates (pmol/min) of WT (black), P234KY 
(green), and ΔETAQ (blue) GARS were plotted against tRNA 
concentrations and fit to the Michaelis-Menten equation. 
(C) Representative cultures of yeast strains lacking GRS1 to 
test for growth in the presence of each mutation (ΔETAQ or 
P234KY) modeled in the human GARS open reading frame. 
(D) WT, P234KY, or ΔETAQ GARS was expressed (with a V5 
tag) and tested by immunoprecipitation with an anti-NRP1 
antibody to detect aberrant interactions. Western blots 
were performed with anti-NRP1 and anti-V5 antibodies. 
Immunoprecipitation (IP), negative control (IgG), and input 
experiments are indicated.
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velocities (NCVs) were reduced by 62%, falling from 35 ± 6.29 
m/s in control animals to 13.5 ± 4.1 m/s (P = 0.0002) in the sciatic 
nerve in mutant mice (Figure 2F). This decrease was consistent 
with other mouse Gars neuropathy models and with some patients 
with GARS-mediated peripheral neuropathy (CMT2D). There was 
a concomitant disruption of neuromuscular junctions (NMJs) in 
distal muscles. While postsynaptic receptor fields of NMJs in the 
plantaris muscle were fully occupied by motor nerve terminals 
body weight (P = 0.0006) and grip strength (P = 0.0002) compared 
with GarshuEx8/+ controls (Figure 2, A and B). Histological changes 
in GarsΔETAQ/huEx8 mice were observed in cross sections of the motor 
branch of the femoral nerve, including an overall decrease in axon 
number (P = 0.0293) and axon diameter (P < 0.0001) (Figure 2, 
C–E). The axon diameters were reduced in the sensory branch 
of the femoral nerve, but the number of myelinated axons was 
unchanged (Supplemental Figure 4, A and B). Nerve conduction 
Figure 2. In vivo characterization of the ΔETAQ GARS variant. (A) GarsΔETAQ/huEx8 mice and littermate controls were weighed at 12 weeks. GarsΔETAQ/huEx8 mice 
were significantly lighter, weighing 19 ± 1.9 g (P = 0.0006, n = 8), compared with GarshuEx8/+ controls, which weighed 27.4 ± 4.84 g (n = 7). (B) Gross motor 
performance in GarsΔETAQ/huEx8 mice was quantified using a wire hang test. While GarshuEx8/+ mice averaged 55 ± 9.57 seconds before letting go, GarsΔETAQ/huEx8 
mice (n = 8) fell after only 17.3 ± 11.3 seconds. (C) Myelinated axon number in the motor branch of the femoral nerve was reduced by 21% from 551 ± 45 axons 
in littermate controls to 438 ± 92 axons in GarsΔETAQ/huEx8 (n = 6 mice per genotype). (D) Axon diameters were reduced, as shown in a cumulative histogram (P 
< 0.0001, Kolmogorov-Smirnov test, average diameter 1.6 ± 0.8 μm, n = 6), in comparison with Gars+/huEx8 littermates (3.3 ± 2.198 μm, n = 6). (E) Represen-
tative images of femoral motor nerve cross sections. (F) Nerve conduction velocity (NCV) was reduced from 35 ± 6.29 m/s in littermate controls to 13.5 ± 4.1 
m/s in GarsΔETAQ/huEx8 mice (P = 0.0002, n = 6 GarsΔETAQ/huEx8, n = 7 GarshuEx8/+). (G) Neuromuscular junctions (NMJs) from the plantaris muscle showed partial 
innervation and denervation, scored based on the overlap between pre- and postsynaptic staining. (H and I) Representative images of NMJ morphology and 
innervation are shown. Differences in body weight, grip strength, conduction, and axon number between genotypes were statistically evaluated using a 
2-way Student’s t test; axon diameter was evaluated by a Kolmogorov-Smirnov test. Significant difference in overall percentage NMJ innervation was deter-
mined by 2-way ANOVA with Tukey’s honestly significant difference (HSD) post hoc comparisons. For all analyses, *P < 0.05, ***P < 0.001, ****P < 0.0001 
represent post hoc significance between genotypes. Values are mean ± SD. Scale bars: 100 μm (E); 50 μm (H, I).
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
5 5 7 2 jci.org   Volume 129   Number 12   December 2019
shuttle designed to specifically target 
ΔETAQ transcripts for degradation 
(Figure 3, A and B, and Supplemen-
tal Figure 5). We designed 6 differ-
ent mir-30–based artificial miRNA 
shuttles (mi.ΔETAQ1–6) with a 
mature guide strand designed to 
specifically target both human and 
mouse mutant Gars ΔETAQ mRNA 
for degradation (Figure 3B and Sup-
plemental Figure 5). To identify 
a lead miRNA shuttle, we cloned 
each mi.ΔETAQ sequence into a U6 
promoter–driven expression cassette. 
These were used in an initial in vitro 
dual-luciferase screening assay (31), 
in which we cloned the ΔETAQ or WT 
Gars target sequences into the 3′-UTR 
of sea pansy (Renilla reniformis) lucif-
erase and used firefly luciferase as 
a standard. Knockdown efficiency 
and disease allele specificity were 
tested following cotransfection of 
the reporter plasmid and each U6.mi.
ΔETAQ shuttle (or a control vector) 
into HEK293 cells. The most effective 
construct (mi.ΔETAQ5, now referred 
to as mi.ΔETAQ) (Figure 3, B and C) 
was cloned into a self-complemen-
tary adeno-associated viral vector 
(serotype 9; scAAV9) for in vivo 
delivery (Figure 3B and Supplemen-
tal Figure 5).
To establish the proof of prin-
ciple of this approach in vivo, we 
tested whether the reduction of 
mutant Gars expression before dis-
ease onset could prevent the neur-
opathy in GarsΔETAQ/huEx8 mice. A dose 
of approximately 2.6 × 1011 viral 
genomes (vg) of scAAV9.mi.ΔETAQ 
or scAAV9.mi.LacZ (expressing a 
control miRNA targeting the E. 
coli LacZ gene) was delivered with 
an intracerebroventricular (i.c.v.) 
injection at postnatal day 0–1 (P0–P1) to GarsΔETAQ/huEx8 and lit-
termate control (GarshuEx8/huEx8) pups. All mice were evaluated 
for established signs of neuropathy at 4 weeks of age, approxi-
mately 1.5 weeks after the initial onset of overt signs of neurop-
athy. GarsΔETAQ/huEx8 mice treated with scAAV9.mi.ΔETAQ showed 
improvement in a wire hang test of grip strength, increased 
muscle-to-body-weight (MW/BW) ratios, and improved sciatic 
nerve conduction velocity (NCV) compared with control-treated 
ΔETAQ mice (Figure 4, A–C). Examination of cross sections of 
the motor branch of the femoral nerve revealed that scAAV9.
mi.ΔETAQ treatment prevented the axon loss and lessened the 
decrease in axon diameters observed in untreated and scAAV9.
in control littermates, 60% ± 14.2% of NMJs were partially occu-
pied and 8.5% ± 9.9% were completely denervated in ΔETAQ 
mice (Figure 2, G–I). Defects in NMJ innervation were evident at 
6 weeks of age, and examples of fully innervated, partially inner-
vated, and denervated junctions are shown in Supplemental Fig-
ure 4, C–G, and resemble those in previously reported Gars mice 
(22, 26–28). Thus, GarsΔETAQ/huEx8 mice display primary features of 
peripheral neuropathy similar to other established mouse models 
of CMT2D, confirming that the ΔETAQ GARS mutation is patho-
genic (22, 26, 29, 30).
To test whether allele-specific knockdown of mutant GARS 
using RNAi would be efficacious, we first engineered a miRNA 
Figure 3. Generation of ΔETAQ-targeting miRNA shuttles. (A) Therapeutic miGARS miRNAs utilize naturally 
occurring RNAi biogenesis and gene silencing pathways in targeting cells. Each miGARS or control sequence 
was cloned as a DNA template downstream of a U6 promoter and then delivered to cells via plasmid transfec-
tion (in vitro) or within scAAV9 particles in vivo (depicted here). Once in the target cell nucleus, primary miRNA 
constructs are transcribed and then processed by the RNAses DROSHA and DICER and the nuclear export 
factor exportin-5 (Exp5). The mature antisense strand (red line) incorporates into the RNA-induced silencing 
complex (RISC) to elicit sequence-specific degradation of the mutant Gars mRNA. (B) MiRNAs were tested 
in vitro by cotransfection of HEK293 cells with U6-miGARS, or control, plasmid miRNA and a dual-luciferase 
reporter plasmid containing 1 of 4 target genes cloned into the 3′-UTR of Renilla luciferase: WT human GARS, 
human ΔETAQ GARS, WT mouse Gars, or the mouse Gars gene containing the same ETAQ deletion. Target 
gene silencing was then determined by measurement of the ratio of Renilla to firefly luciferase. The values are 
reported as mean ratios ± SEM. (C) The sequence of the guide strand of the lead mi.ΔETAQ and its comple-
mentarity to both the WT and ΔETAQ GARS gene. The 4–amino acid deletion is shown in red. Base pairing 
between the miRNA and target genes is shown with vertical lines, with red lines indicating wobble G-U bonds 
present in RNA duplexes.
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mi.LacZ-treated ΔETAQ mice (Figure 4, D–F). Injection with 
scAAV9.mi.ΔETAQ (or scAAV9.mi.LacZ) did not cause adverse 
effects in control mice. Collectively, these data provide the proof 
of concept that allele-specific knockdown using virally delivered 
RNAi may be an effective approach for treating CMT2D.
We next delivered scAAV9.mi.ΔETAQ to cohorts of both early- 
symptomatic (5-week-old) and late-symptomatic (9-week-old) 
GarsΔETAQ/huEx8 mice and littermate controls via a single intrathe-
cal injection into the lumbar spinal cord. When left untreated, 
5-week-old early-symptomatic GarsΔETAQ/huEx8 mice undergo active 
axon loss, while axon loss slows and muscle atrophy accelerates in 
9-week-old late-symptomatic ΔETAQ mice.
The scAAV9.mi.ΔETAQ-treated early-symptomatic GarsΔETAQ/huEx8 
mice displayed enhanced grip strength and increases in body weight 
starting at about 5 weeks after treatment compared with untreated 
controls (Figure 5A). When analyzed for primary signs of neurop-
athy at 7 weeks after treatment, early-symptomatic GarsΔETAQ/huEx8 
mice also exhibited significant increases in MW/BW ratios, NCV, 
and NMJ innervation and a reduction in axon loss but no improve-
ment in axon size compared with untreated GarsΔETAQ/huEx8 mice 
(Figure 5, B–D and F). When treated with scAAV9.mi.ΔETAQ at 
9 weeks of age, GarsΔETAQ/huEx8 mice gained weight and displayed 
enhanced grip strength starting at 5–7 weeks after treatment (Fig-
ure 5A). While MW/BW ratios were not improved and axon loss 
and atrophy were not prevented, scAAV9.mi.ΔETAQ did improve 
NCV and NMJ innervation (Figure 5, B, E, and F). Analysis of mRNA 
from sensory dorsal root ganglia (DRGs), which are also transduced 
by scAAV9, via pyrosequencing indicated that mutant Gars mRNA 
levels were significantly reduced in scAAV9.mi.ΔETAQ-treated 
mice (Supplemental Table 2).
We also evaluated possible off-target effects of the RNAi. In 
addition to prediction programs, we also empirically tested for 
gene expression changes and found 325 genes that were altered 
in their expression with an FDR less than 0.05 based on RNA-
Seq of patient fibroblasts transfected with the mi.ΔETAQ con-
struct in comparison with eGFP transfection as a control. The 
physiological significance of these changes is unknown, and the 
transcriptome of fibroblasts will be only partially shared with 
that of neurons. To evaluate possible adverse effects in vivo, WT 
mice were treated with the same dose of vector by intrathecal 
injection (30 seven-week-old female mice comprising 3 groups: 
10 mi.ΔETAQ treated, 10 mi.LacZ treated, and 10 untreated). 
No adverse effects other than a mild increase in germinal cen-
ter activity in the spleen were seen 10 weeks after treatment 
after full necropsy and evaluation by a veterinary pathologist 
blinded to treatment.
We confirmed the efficacy of allele-specific knockdown in 
a second mouse model of CMT2D, GarsP278KY/+ (22). A miRNA 
Figure 4. scAAV9.mi.ΔETAQ treatment prevents the onset of neuropathy in ΔETAQ mice. (A–C) Neonatal scAAV9.mi.ΔETAQ treatment significantly 
prevented deficits in gross motor performance quantified by the wire hang test (P = 0.0001) as well as reductions in MW/BW ratios (P = 0.0315) and NCVs 
(<0.0001), in comparison with untreated or vehicle-treated GarsΔETAQ/huEx8 mice. (D–F) Quantification of axon number and axon size indicated that scAAV9.
mi.ΔETAQ could partially prevent axon loss (P = 0.0272) and reductions in axon diameter (P ≤ 0.0001) in comparison with scAAV9.mi.LacZ-treated ΔETAQ 
mice, as shown in cross sections of the motor branch of the femoral nerve. Axon diameter was analyzed using a Kolmogorov-Smirnov normality test, while 
all other outcome measures were analyzed using a 2-way ANOVA with Tukey’s HSD post hoc comparisons. *P < 0.05, ****P < 0.0001 represent post hoc 
significance between scAAV9.mi.ΔETAQ- and scAAV9.mi.LacZ-treated ΔETAQ mice. Values are mean ± SD. Scale bars: 100 μm. Untreated GarshuEx8/huEx8,  
n = 4; mi.LacZ-treated GarshuEx8/huEx8, n = 3; scAAV9.mi.ΔETAQ-treated GarshuEx8/huEx8, n = 5; mi.LacZ-treated GarsΔETAQ/huEx8, n = 5; and scAAV9.mi.ΔETAQ- 
treated GarsΔETAQ/huEx8, n = 5.
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i.c.v. injection (Supplemental Figure 8), consistent with the need 
to target the nervous system and not peripheral tissues.
The beneficial effects of i.c.v. delivery of the high dose (1 × 
1011 vg) of scAAV9.mi.P278KY at P0 lasted at least 1 year (Fig-
ure 7). Treated mice maintained more normal body weights than 
sham-treated controls (Figure 7A). They also maintained their 
normal performance in the wire hang test (Figure 7B). One year 
after treatment, the GarsP278KY/+ mice did not show signs of muscle 
atrophy, reduced NCV, axon loss, or axon atrophy (Figure 7, C–G). 
Thus, consistent with the perdurance of AAV9, a single dose at 
birth prevented neuropathy for at least 1 year.
The outcomes in post-onset studies in both genotypes were 
variable, likely because of the challenges in intrathecal delivery 
in mice. However, the knockdown efficacy of mutant Gars tran-
scripts within DRGs (Supplemental Tables 2–4) correlated with 
therapeutic outcomes within both post-onset studies (Supplemen-
tal Figure 9, A, B, E, and F). This correlation was stronger with 
mRNA isolated from DRGs than when outcomes were compared 
with mutant Gars mRNA levels in liver, another tissue transduced 
by scAAV9 (Supplemental Figure 9, C, D, G, and H). This is con-
sistent with the benefit coming from the transduction of cells with 
direct delivery to the nervous system and not from transduction of 
peripheral organs.
Discussion
In this study we examined a new de novo variant of GARS, 
ΔETAQ, identified in a patient with an early-onset motor neu-
ropathy. Although not unprecedented, the severity and onset of 
this case are atypical for CMT2D (14). Biochemical characteriza-
tion of the mutation revealed a loss of activity in the charging of 
glycine onto tRNAGly, consistent with other pathogenic alleles of 
GARS (18). However, in contrast to other pathogenic alleles (23), 
the mutant protein does not strongly bind to NRP1. Given the 
atypical clinical presentation and biochemical properties of the 
ΔETAQ variant, we confirmed its pathogenicity by introducing 
the same change into the mouse Gars gene. Mice carrying this 
dominant mutation developed a severe, early-onset peripheral 
neuropathy, confirming that it is indeed disease-causing. We 
next developed an allele-specific-knockdown vector to target 
mutant Gars transcripts while leaving the WT Gars mRNA intact. 
RNAi sequences were optimized in vitro and cloned into a miR-
30 shuttle construct driven by a U6 promoter, which was pack-
aged into scAAV9 for in vivo delivery. Treatment of the mouse 
model at birth by i.c.v. injection was able to largely prevent the 
onset of neuropathy, and delivery by intrathecal injection after 
the onset of symptoms still had benefit, though the degree of 
benefit decreased as delivery of the treatment was delayed. 
These results were confirmed in a second mouse model of 
CMT2D, carrying a mutation (P278KY) not found in patients. 
In these mice, an allele-specific knockdown vector delivered 
as above produced similar benefit, both before and after onset. 
These effects were dose dependent and persisted for at least 1 
year. The improvement in neuropathy phenotypes correlated 
with the degree of knockdown of the mutant Gars mRNA. Thus, 
our findings support the feasibility of virally delivered RNAi for 
allele-specific knockdown as a treatment strategy for a dominant 
neuropathy caused by mutations in an essential gene.
shuttle targeting the mouse P278KY allele was optimized as before 
and packaged into scAAV9 (Supplemental Figure 6). As with the 
ΔETAQ vector, improvements were observed in neonatal, early- 
and late-symptomatic GarsP278KY/+ mice that were treated with 1 
× 1011 vg of scAAV9.mi.P278KY delivered by i.c.v. (neonates) or 
intrathecal (adults) injection (Figure 6 and Supplemental Figure 
7). GarsP278KY/+ mice treated with the therapeutic vector at P0–P1 
showed WT performance in the wire hang test (Figure 6A), and 
did not show signs of muscle atrophy, reduced NCV, or axon loss 
when examined at 4 weeks of age (Figure 6, B–D). Axon diame-
ters in the motor branch of the femoral nerve and innervation at 
the NMJ were both improved over untreated or scAAV9.mi.LacZ- 
treated mice, but were not preserved to WT levels (Figure 6, E–H). 
No adverse effects were noted in WT mice treated with this vector. 
When treated after the onset of disease at 5 or 9 weeks of age, these 
mice improved in their grip strength and body weights over the next 
7 weeks to a greater extent than mice treated with the lacZ vector 
(Supplemental Figure 7). While muscle atrophy was reduced with 
treatment at 5 weeks of age, it was not improved with treatment at 9 
weeks, and NCV was not improved at either time point (Supplemen-
tal Figure 7). However, innervation at the NMJ was improved at both 
ages (Supplemental Figure 7).
The therapeutic effects of scAAV9.mi.P278KY were dose 
dependent, and were greater with i.c.v. delivery compared with 
a systemic, i.v. injection delivering the same total dose (Supple-
mental Figure 8). With i.c.v. delivery, doses including 1 × 1010, 5 × 
1010, and 1 × 1011 vg all showed dose-dependent improvement over 
untreated mice, with 1 × 1011 achieving near-complete prevention 
of the neuropathy (Figure 6 and Supplemental Figure 8). Deliver-
ing 1 × 1011 vg systemically by i.v. injection produced benefit com-
parable to 1 × 1010 vg delivered directly to the nervous system by 
Figure 5. Post-onset therapeutic effects of scAAV9.mi.ΔETAQ. (A) Reduc-
tion in mutant Gars expression improved grip strength and increased body 
weight in early- and late-symptomatic GarsΔETAQ/huEx8 mice. Mi.ΔETAQ-treated 
early- and late-symptomatic GarsΔETAQ/huEx8 mice exhibited enhanced grip 
strength and significant increases in body weight starting at approximately 
5 weeks after treatment. When evaluated at 7 weeks after treatment for 
signs of neuropathy, these data correlate with trending increases in MW/
BW ratios and significant improvements in NCV in mi.ΔETAQ-treated 
late-symptomatic GarsΔETAQ/huEx8 mice. (B–D) Early-symptomatic GarsΔETAQ/huEx8 
mice treated with mi.ΔETAQ displayed significantly higher MW/BW ratios 
and faster NCVs (B), most likely resulting from the greater number of motor 
axons observed in cross sections of the motor branch of the femoral nerve, 
although improvement in axon diameter was not observed (C and D). (E) 
Prevention of axon loss was not observed in mi.ΔETAQ-treated late- 
symptomatic GarsΔETAQ/huEx8 mice. (F) Both early- and late- symptomatic 
overall displayed significant increases in NMJ innervation. Data were analyzed 
using a 1-way ANOVA followed by Tukey’s HSD post hoc comparisons. Signifi-
cant changes in axon diameter (E) were determined with a Kolmogorov- 
Smirnov test. *P < 0.05, **P < 0.01, ***P < 0.001 represent post hoc signifi-
cance between mi.LacZ-treated and scAAV9.mi.ΔETAQ-treated GarsΔETAQ/huEx8 
mice. #Significant difference in fully innervated NMJs; §significant difference 
in partially innervated NMJs; †significant difference in denervated NMJs. 
Late-symptomatic cohort: mi.LacZ-treated GarshuEx8/huEx8, n = 5–7; scAAV9.
mi.ΔETAQ-treated GarshuEx8/huEx8, n = 3–5; mi.LacZ-treated GarsΔETAQ/huEx8,  
n = 6; and scAAV9.mi.ΔETAQ-treated GarsΔETAQ/huEx8, n = 7. Early-symptomatic 
cohort: GarshuEx8/huEx8, n = 6–7; scAAV9.mi.ΔETAQ-treated GarshuEx8/huEx8,  
n = 3–5; mi.LacZ-treated GarsΔETAQ/huEx8, n = 7; and scAAV9.mi.ΔETAQ-treated 
GarsΔETAQ/huEx8, n = 9–11. Values are mean ± SD. Scale bars: 100 μm.
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Figure 6. Reduction of mutant Gars by RNAi prevents neuropathy in GarsP278KY/+ mice. (A and B) Neonatal scAAV9.mi.P278KY treatment prevented deficits in 
gross motor performance quantified at 4 weeks of age by the wire hang test (P = 0.0001) (A) and reductions in MW/BW ratios (P = 0.0463) (B) in comparison 
with untreated and vehicle-treated P278KY mice. (C) NCVs were also significantly improved (P ≤ 0.0001) in treated P278KY mice. (D) Quantification of axon 
number within cross sections of the motor branch of the femoral nerve showed that while axon number was reduced by 17% in control-treated P278KY mice, 
axon counts in scAAV9.mi.P278KY-treated P278KY mice (589 ± 15 axons) were similar to those in untreated control littermates (600 ± 11 axons). (E) scAAV9.
mi.P278KY treatment also restored the presence of large-diameter axons; average axon diameter was 1.98 ± 4.47 μm in control-treated P278KY mice, 2.71 ± 
3.71 μm in scAAV9.mi.P278KY-treated P278KY mice, and 3.84 ± 3.74 μm in untreated Gars+/+ mice. (F) Representative images of cross sections of the motor 
branch of the femoral nerve isolated from untreated Gars+/+, GarsP278KY/+, and scAAV9.mi.P278KY-treated GarsP278KY/+ mice. (G) Representative images of NMJ 
morphology isolated from plantaris muscle. (H) While over 70% of the NMJs were partially or completely denervated in control-treated GarsP278KY/+ mice by 4 
weeks of age, less than 30% of NMJs showed any degree of denervation in scAAV9.mi.P278KY-treated GarsP278KY/+ mice. Numbers for all outcome measures: 
untreated Gars+/+, n = 5; control-treated Gars+/+, n = 4; scAAV9.mi.P278KY-treated Gars+/+, n = 8; untreated GarsP278KY/+, n = 6; control-treated GarsP278KY/+, n = 5; 
scAAV9.mi.P278KY-treated GarsP278KY/+, n = 7. Significance in A–D and H was determined by 2-way ANOVA with Tukey’s HSD post hoc comparisons. Signif-
icant changes in axon diameter (E) were determined with a Kolmogorov-Smirnov test. *P < 0.05, ****P < 0.0001 represent post hoc significance between 
mi.LacZ-treated and scAAV9.mi.P278KY-treated GarsP278KY/+ mice. Values are mean ± SD. All scale bars: 100 μm.
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essential for pathogenicity. Importantly, our allele-specific knock-
down approach applies equally well to a dominant-negative or a 
neomorphic mechanism.
Our results also serve as a preclinical demonstration of the 
feasibility of RNAi-mediated allele-specific knockdown as a 
therapeutic strategy. Pre-onset treatments were able to almost 
completely prevent the neuropathy. This provides strong proof-
of-concept data for the effectiveness of knocking down mutant 
GARS. Post-onset treatment still provided benefit, though this 
was less complete and diminished the longer treatment was 
withheld. The post-onset treatment may stop or slow the pro-
gression of axon loss. This is best demonstrated by the reduc-
tion in axon loss seen in ΔETAQ mice treated at 5 weeks of age 
compared with untreated mutant mice (Figure 5D), but there 
was no similar reduction with treatment at 9 weeks of age (Fig-
ure 5E), an age by which most of the axons have already degen-
The disease mechanism through which mutant forms of 
GARS cause CMT2D is not clear. Variants of GARS that result in 
neuropathy impact the enzymatic activity of the protein to varying 
degrees. Since alleles that do not produce a mutant protein do not 
cause a dominant disease in mice or humans, a loss-of-function 
mechanism underlying the neuropathy would have to be through a 
dominant-negative mechanism. Alternatively, neomorphic gain-
of-function activities are consistent with findings in mouse and 
Drosophila models (20, 32). Mutant forms of GARS bind to NRP1, 
an important neurodevelopmental receptor that transduces both 
VEGF and semaphorin signals, whereas WT GARS does not bind 
NRP1 (23). This aberrant interaction interferes with VEGF bind-
ing, possibly constituting a pathogenic neomorphic activity of the 
mutant protein. However, our finding that the ΔETAQ form of 
GARS does not have a strong interaction with NRP1 indicates that 
while this mechanism may still contribute to the disease, it is not 
Figure 7. Long-term therapeutic effects of 
neonatal scAAV9.mi.P278KY treatment. (A 
and B) scAAV9.mi.P278KY-treated P278KY 
mice displayed increases in body weight (A) 
starting at 24 weeks after treatment and in 
grip strength (B) throughout the course of 1 
year compared with vehicle control–treated 
P278KY mice. (C and D) When evaluated for 
primary signs of neuropathy at 1 year after 
treatment, treated P278KY mice exhibited 
greater MW/BW ratios (C) and faster NCVs 
(D). (E–G) scAAV9.mi.P278KY treatment 
could preserve all populations of axons in 
the motor branch of the femoral nerve at 
1 year after treatment. Significance in A 
and B was determined by 1-way ANOVA 
with Tukey’s HSD post hoc comparisons. 
Significance in C, D, and F was determined 
by 2-way ANOVA with Tukey’s HSD post 
hoc comparisons. Significant changes in 
axon diameter (G) were determined with a 
Kolmogorov-Smirnov test. Mi.LacZ-treated 
Gars+/+, n = 3; scAAV9.mi.P278KY-treated 
Gars+/+, n = 3; mi.LacZ-treated GarsP278KY/+, 
n = 5; and scAAV9.mi.P278YK-treated  
GarsP278KY/+, n = 7. Values are mean ± SD.
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be combined with other strat egies to promote regeneration to 
achieve a better recovery of function.
In summary, these studies demonstrate how precision ani-
mal models can be used for testing personalized therapies for 
rare and orphan diseases, and provide important proof of con-
cept for RNAi-based gene therapy for this dominant disease. 
This approach could be applied to other, related disorders 
including other dominantly inherited peripheral neuropathies 
or motor neuron diseases.
Methods
Clinical evaluation and mutation analysis. The proband was clinically 
evaluated at Texas Children’s Hospital (Houston, Texas, USA). Diag-
nostic, whole-exome sequencing (XomeDxPlus) was performed by 
GeneDx (Gaithersburg, Maryland, USA). For allele-specific Sanger 
sequencing, we first isolated DNA from patient-derived primary fibro-
blasts. Cells were treated with trypsin according to the Wizard Genomic 
DNA Purification Kit (Promega) protocol. PCR amplification was per-
formed to obtain a 381-bp region including GARS exon 8 using PCR 
SuperMix (Thermo Fisher Scientific). PCR products were cloned with 
the TOPO TA Cloning Kit (Thermo Fisher Scientific). Plasmid DNA 
from 6 isolated colonies was purified and Sanger-sequenced using 
the PCR primers: forward 5′-GCATTGCCAAAGTAGTACTGC-3′ and 
reverse 5′-CCTGACTCTGATCAGTCCAGATCG-3′.
GARS expression studies
For RNA expression studies, RNA was isolated from patient fibroblasts 
using the RNeasy Mini Kit (Qiagen). cDNA was generated from 1 μg of 
RNA using the High-Capacity cDNA reverse transcription kit (Applied 
Biosystems). The resulting cDNA was used to amplify a 224-bp prod-
uct including the ΔETAQ GARS mutation. The reaction was column 
purified and checked for quality via gel electrophoresis. For next- 
generation sequencing, the product was digested and “tagmented” 
using Tn5 transposase. The library was amplified by PCR using Kapa 
Hifi DNA polymerase and Illumina-compatible indexing primers. Final 
library fragment size and purity were determined via gel electropho-
resis, and fragments were column purified and sequenced on the Illu-
mina MiSeq with paired 155-bp reads. Overlapping reads were merged 
using PEAR (version 0.9.6) and aligned using BWA MEM (version 
0.7.12) to custom references containing the WT exon 7/exon 8 junction 
or the ΔETAQ-containing equivalent. A custom Python script (https://
github.com/kitzmanlab/gars_burgess_2019) was used to count reads 
with higher-scoring alignment to each junction. Uninformative reads 
(e.g., those not spanning the mutation) were disregarded.
For fibroblast protein expression studies, proteins were isolated 
in 1 mL cell lysis buffer (990 μL RIPA Lysis Buffer [Thermo Fisher 
Scientific] plus 10 μL 100× Halt Protease Inhibitor [Thermo Fisher 
Scientific]) and quantified using the Pierce BCA Protein Assay Kit 
(Thermo Fisher Scientific). Ten micrograms of protein per sample 
was analyzed via Western blot. Samples were prepared in 1× SDS 
sample buffer (Thermo Fisher Scientific) plus 5 μL β-mercaptoeth-
anol and boiled at 99°C for 10 minutes, then separated on precast 
4%–20% Tris-glycine gels (Thermo Fisher Scientific), transferred 
onto a PVDF membrane, and probed with the respective primary 
antibody at the following dilutions in blocking solution: anti-
GARS 1:1000, described in ref. 17; anti-NRP1 (Abcam, EPR3113) 
1:1000; and anti-actin (Sigma-Aldrich, A5060) 1:5000. Mem-
erated. Even with axon loss, some of the residual benefit may 
come from improved synaptic transmission at NMJs, consis-
tent with the improved innervation and with previous findings 
that synaptic transmission is progressively impaired in Gars 
mutant mice (28).
Another important consideration for the translational poten-
tial of this approach is whether we can achieve sufficient allelic 
specificity with single–base pair mutations. The mutations that 
we targeted here differed from WT sequence by 5 (P278KY) or 
12 (ΔETAQ) bp, making them relatively good targets for specific 
RNAi sequences. Allele specificity of RNAi for single-nucleo-
tide differences will depend on surrounding local sequence, but 
is precedented, and efficiency can be improved by addition of 
additional mismatches to the RNAi sequence (33–35). Therefore, 
a similar allele-specific knockdown strategy may be effective for 
additional alleles of GARS. An alternative strategy that would 
apply equally to any allele of GARS would be to knock down all 
GARS transcripts, mutant and WT, using a nonspecific GARS 
RNAi, and, in the same vector, provide an RNAi-resistant WT 
cDNA. This strategy has been used for α1-antitrypsin (36). Other 
strategies, such as allele-specific antisense oligonucleotides or 
allele-specific CRISPR/Cas9 gene editing, could also be used 
to silence mutant GARS alleles while preserving WT GARS, but 
would require additional development.
The reduced efficacy of the treatment after the onset of 
neuropathy will be complicated to dissect. It is possible that the 
intrathecal delivery or reduced transduction efficiency of adult 
peripheral neurons contributed to the reduced efficacy. Intra-
thecal delivery was chosen as it is the route of delivery in gene 
therapy trials for related disorders (6). In our study, the degree of 
improvement in outcomes such as NCV correlated with the extent 
of the knockdown of mutant Gars relative to WT Gars transcripts 
assayed by PCR in sensory DRGs (Supplemental Figures 7 and 8). 
We chose to assay DRGs because they are efficiently transduced 
and the sensory neurons comprise a large proportion of the tissue 
mass, providing the best opportunity to assess the efficiency of the 
knockdown. However, this analysis does not resolve this question 
on a cell-by-cell basis, nor does it address knockdown in motor 
neurons. The biodistribution of AAV9 in mice and other animals 
has been previously reported (37–39), and therefore, we did not 
repeat those analyses here. However, in pilot studies using AAV9-
GFP, we saw transduction in spinal cord and DRGs that closely 
matched published results.
Despite the unknowns regarding transduction efficiency and 
the extent of the knockdown, the benefit observed with post-onset 
delivery is encouraging. However, it is notable that we also did not 
see regeneration. The axon numbers did not increase when treat-
ment was delivered after axon loss. Similarly, at NMJs, there was 
no evidence of collateral sprouting and reinnervation of dener-
vated NMJs by the remaining axons. It is unclear whether this is 
due to insufficient knockdown of the mutant mRNA, or whether 
the axon degeneration is irreversible. The fact that the results 
were so similar in both mouse models despite the knockdown of 
the P278KY allele being so efficient in vitro may suggest that the 
degeneration is irreversible under normal circumstances. There-
fore, the benefit of treatment after the onset of symptoms may 
be limited to slowing or stopping progression, and may need to 
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mouse MN1 cells in 2004 from Kurt Fischbeck (NIH/National Insti-
tute of Neurological Disorders and Stroke, Bethesda, Maryland, USA), 
who obtained them directly from the laboratory that generated these 
cells (H. Kim, University of Chicago, Chicago, Illinois, USA) (42). Cells 
were transfected using Lipofectamine 2000 (Invitrogen) with 15 μg 
of a plasmid to express WT or mutant GARS pTM3xFLAG per T-175 
flask. Cells were incubated for 48 hours at 37°C in 5% CO2. Cells were 
then harvested using 0.25% trypsin (Invitrogen), centrifuged at 805 g 
for 2 minutes, and washed twice with 1× PBS.
Coimmunoprecipitation analyses
Twenty-five microliters of Dynabeads Protein G Magnetic beads 
(Invitrogen) were used for each cell lysate from one T-175 flask. 
Beads were washed twice in 1 mL of wash solution (0.5% BSA and 
0.1% Triton X-100 in PBS) and resuspended in 1 mL of wash solu-
tion. Two micrograms anti-FLAG antibody (Sigma-Aldrich, clone 
M2) was added and incubated at 4°C with gentle shaking overnight. 
Transfected cells were resuspended in 1.5 mL lysis buffer (20 mM 
Tris-HCl [pH 7.5], 2.5 mM MgCl2, 300 mM KCl, 0.1% NP-40, 1 mM 
DTT, 0.2 mM PMSF, 1× Halt Protease Inhibitor Cocktail [EDTA free] 
[Thermo Fisher Scientific]) and incubated with gentle rocking at 4°C 
for 90 minutes. Cell lysates were centrifuged at 17,800 g for 5 minutes 
at 4°C. The supernatant was removed and used as the input for the 
immunoprecipitation (IP) reaction. Protein was quantified using the 
Pierce BCA Protein Assay Kit (Thermo Fisher Scientific), and 1 mg of 
protein was used as input. Expression of 3xFLAG-tagged protein in 
input samples was confirmed by anti-FLAG M2 Western blotting. The 
αFLAG-conjugated magnetic beads were washed twice with 500 μL 
of lysis buffer, resuspended in 25 μL lysis buffer, and added to the pro-
tein sample. After 2 hours of incubation at 4°C with gentle shaking, 
beads were magnetically isolated, washed 5 times with 1 mL of buffer 
(20 mM Tris-HCl [pH 7.5], 2.5 mM MgCl2, 300 mM KCl, 0.1% NP-40, 
1 mM DTT), and resuspended in 30–50 μL of wash buffer per 25 μL 
of starting beads. Two hundred micrograms per milliliter of 3xFLAG 
peptide was added to each sample and incubated at 4°C with gentle 
shaking for 3 hours to elute the FLAG-tagged protein.
Mass spectrometry and bioinformatics
For mass spectrometry at the Fred Hutchinson Cancer Institute, IP 
products were separated on a denaturing 4%–20% Tris-glycine gel and 
silver-stained using standard protocols. Destained gel slices were used 
for in-gel digestion with an ice-cold solution of 12.5 ng/μL trypsin in 
50 mM ammonium bicarbonate on ice for 1 hour. The trypsin solution 
was removed and replaced with 50 mM ammonium bicarbonate, and 
digestion was carried out overnight at 37°C. Peptides were extracted 
by the addition of 0.1% trifluoroacetic acid and light vortexing for 30 
minutes followed by addition of an equal volume of 100% acetonitrile 
and light vortexing for an additional 30 minutes. Desalted samples 
were brought up in 10 μL of 2% acetonitrile in 0.1% formic acid, and 8 
μL was analyzed by liquid chromatography/electrospray ionization tan-
dem mass spectrometry (MS/MS) using an Easy-nLC 1000 (Thermo 
Fisher Scientific) HPLC system coupled to a hybrid Orbitrap Elite 
(Thermo Fisher Scientific) as previously described (43). The Orbitrap 
Elite instrument was operated in the data-dependent mode, switch-
ing automatically between mass spectrometric survey scans in the 
Orbitrap with MS/MS spectra acquisition in the linear ion trap. The 15 
most intense ions from the Fourier transform full scan were selected 
branes were then rinsed 3 times in 1× TBST to remove unbound 
antibody and incubated with the respective HRP-conjugated 
secondary antibody at 1:10,000. Membranes were rinsed in 1× TBST 
and exposed using SuperSignal West Dura substrate and enhancer 
(Thermo Fisher Scientific).
Expression construct development
All GARS expression constructs were generated using Gateway clon-
ing (Invitrogen). The human GARS open reading frame was ampli-
fied from human cDNA using primers with the attB1 (forward, GARS 
ORF F = ATGGACGGCGCGGGGGCTGAGG) and attB2 (reverse, 
GARS ORF R = TCATTCCTCGATTGTCTCT) Gateway sequences. 
Entry clones were generated by recombination of PCR-purified 
amplicons into the pDONR221 vector using BP clonase. Individual 
WT entry clones were confirmed by sequencing. Oligonucleotides 
containing sequences corresponding to each GARS mutation studied 
were generated, and mutagenesis was performed using the Quik-
Change II XL Site-Directed Mutagenesis Kit (Stratagene). Individual 
clones were sequenced to confirm each mutation and the absence of 
errors. Validated entry clones were recombined into the appropriate 
Gateway-compatible vector using LR clonase: pET-21a(+) for amino-
acylation assays and pTM3xFLAG for coimmunoprecipitation assays. 
For yeast complementation assays, human GARS was expressed from 
the pYY1 expression construct containing ΔMTSΔWHEP GARS; the 
pYY1 constructs were a gift from Chin-I Chien and Chien-Chia Wang 
(National Central University, Taoyuan City, Taiwan).
Aminoacylation assays
WT and mutant GARS proteins were expressed in E. coli with a 
C-terminal His tag and purified with nickel affinity resins (Novagen). 
The T7 transcript of human tRNAGly/CCC (CCC, anticodon) was pre-
pared and purified as previously described (40), heat-denatured 
at 85°C for 3 minutes, and annealed at 37°C for 20 minutes before 
use. Steady-state aminoacylation assays were monitored at 37°C in 
50 mM HEPES (pH 7.5), 20 mM KCl, 10 mM MgCl2, 4 mM DTT, 2 
mM ATP, and 50 μM 3H-glycine (PerkinElmer) at a specific activity 
of 16,500 dpm/pmol. The reaction was initiated by mixing of GARS 
enzyme (20 nM for WT enzyme and 600 nM for the ΔETAQ and 
P234KY mutants) with varying concentrations of tRNA (0.3–20 μM). 
Aliquots of a reaction mixture were spotted on filter paper, quenched 
by 5% trichloroacetic acid, washed, dried, and measured for radio-
activity using a liquid scintillation counter (LS6000SC, Beckman 
Coulter Inc.). The amount of radioactivity retained on filter pads was 
corrected for quenching effects to determine the amount of synthesis 
of Gly-tRNAGly. Steady-state kinetics was determined by fitting of the 
initial rate of aminoacylation as a function of tRNA concentration to 
the Michaelis-Menten equation (41).
Yeast complementation assays
Yeast complementation assays were carried out as previously 
described (17, 18). At least 2 colonies per transformation were assayed, 
and each transformation was repeated at least twice.
MN1 transfections for immunoprecipitation
MN1 cells were grown at 37°C in 5% CO2 and standard growth medium 
(DMEM supplemented with 10% FBS, 2 mM l-glutamine, 100 U/mL 
penicillin, and 50 μg/mL of streptomycin [Invitrogen]). We obtained 
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mentarity to the target (Gars; GARS), less than 60% GC content of the 
mature duplex, and guide-strand biasing, such that the last 4 nucleo-
tides of the antisense 5′ end were A:U rich, and the last 4 nucleotides 
of the antisense 3′ end were G:C rich. Mutant GARS/Gars–targeting 
miRNA constructs were designed with the seed match region target-
ing the differing nucleotides present in the mutant Gars alleles and 
intentional mismatches with WT GARS/Gars. MiRNAs were cloned 
into a U6T6 expression vector (31). After in vitro testing, lead candi-
date U6.miRNAs were cloned into a self-complementary proviral AAV 
plasmid containing a CMV-driven eGFP reporter. scAAV9 viruses 
were generated and titered by the Viral Vector Core at The Research 
Institute at Nationwide Children’s Hospital (Columbus, Ohio, USA).
Luciferase assays
The dual-luciferase plasmids were created in the Psicheck2 vector 
(Promega), with firefly luciferase serving as a control, and the vari-
ous Gars target regions cloned downstream of the Renilla lucifer-
ase stop codon. HEK293 cells were cotransfected (Lipofectamine 
2000, Invitrogen) with the appropriate reporter and an individual 
U6.miRNA expression plasmid in a 1:5 molar ratio. GARS silencing 
was determined 24 hours after transfection, using the Dual-Lucifer-
ase Reporter Assay System (Promega). Triplicate data were averaged, 
and knockdown significance was analyzed by 2-way ANOVA. Results 
are presented as the mean ratio of Renilla to firefly ± SEM.
Mice
Mice were housed in the research animal facility at The Jackson Lab-
oratory and provided with food and water ad libitum. Gars (CAST;B6- 
GarsNmf249/Rwb; referred to as GarsP278KY/+) are previously described 
(22). The official strain designations of the newly engineered mouse 
models are B6;FVB-Gars<em1Rwb>/Rwb (referred to as GarshuEx8) and 
B6;FVB-Gars<em2Rwb>/Rwb (referred to as GarsΔETAQ/+). Experimen-
tal cohorts used for direct comparisons consisted of littermates.
Generation of GarsΔETAQ/+) and Gars+/huEx8)models with CRISPR/Cas9 
genome-editing technology
Donor constructs. For GarshuEx8/+, the mouse exon 8 sequence was 
replaced with a donor vector containing the human exon 8 sequence. 
The donor was a 10-kb sequence containing a 2.8-kb 5′ arm of 
homology and a 7-kb 3′ arm of homology isolated from a C57BL/6J 
BAC library flanking the human exon 8 sequence. For GarsΔETAQ/+, 
the donor construct consisted of an single-stranded oligonucleotide 
sequence spanning the first 52 bases of mouse exon 8 with short arms 
of homology (see below for sequence) containing a 12-base deletion 
(bases 12–23 of exon 8).
Microinjection. Preparation and microinjection of CRISPR/
Cas9 reagents were performed as previously described (47). All 
components, including Cas9 mRNA (100 ng/μL; either TriLink or 
synthesized by in vitro transcription), sgRNA, guides 144 and 1340 
(50 ng/μL; guide sequence below), and each donor vector (20 ng/
μL plasmid DNA or 100 ng/μL single-stranded donor oligonucle-
otides), were injected into the male pronucleus and cytoplasm of 
about 300 zygotes at the pronuclei stage. All zygotes were isolated 
from superovulated FVB/NJ (JAX stock 001600, The Jackson Lab-
oratory) females mated with C57BL/6NJ (JAX stock 005304) males. 
Then, groups of 15–25 blastocysts were transferred into the uterus of 
pseudopregnant females.
for fragmentation in the linear trap by collision-induced dissociation 
with normalized collision energy of 35%. Selected ions were dynam-
ically excluded for 30 seconds with a list size of 500 and exclusion 
mass width of +/– 10 ppm.
For mass spectrometry at the University of Michigan (Ann Arbor, 
Michigan, USA), IP products were concentrated using TCA precipita-
tion. Two microliters of 2% sodium deoxycholate was added to 200 μL 
of IP product and incubated on ice for 30 minutes. Twenty microliters 
of 100% (wt/vol) TCA was added (bringing TCA to ~10%) and incu-
bated on ice for 1 hour. The product was then centrifuged at maximum 
speed at 4°C for 10 minutes, and the pellet was washed in 500 μL of 
acetone and incubated on ice for 10 minutes. The acetone solution 
was centrifuged at maximum speed at 4°C for 10 minutes. The result-
ing pellet was resuspended in 30 μL of 20 mM HEPES and 8 M urea 
(pH 8.0). Three independently generated IP products for each WT, 
ΔETAQ, and an untagged WT GARS sample were analyzed. MS/MS 
was performed using the Orbitrap Fusion Mass Spectrometer (Thermo 
Fisher Scientific).
For all mass spectrometry data analyses, the open-source pro-
teomics search engine X! Tandem (The Global Proteome Machine 
Organization) was used to match mass spectrometry data with pep-
tide spectra. Peptide Prophet was used to validate peptide assign-
ments (43), and Protein Prophet grouped peptides into proteins (44). 
ABACUS extracted spectral counts for quantitative analysis (45). 
Finally, interactions were scored to remove background, and compar-
isons of interacting proteins were performed to calculate the relative 
fold changes for interactions between WT and ΔETAQ GARS.
Targeted assessment of NRP1-GARS interactions
NSC-34 cells (ATCC) were grown to 70% confluence before transfec-
tion. Human WT, P234KY, or ΔETAQ GARS cDNAs were subcloned 
into the pcDNA6 plasmid in-frame with a V5 tag. Transfections were 
performed using Lipofectamine 2000 (Invitrogen). Thirty-six hours 
after transfection, cells were washed twice in PBS, scraped into PBS, 
pelleted, and resuspended in Pierce IP Lysis Buffer (Thermo Fisher 
Scientific) for 30 minutes and centrifuged for 7 minutes at 12,000 
g; the insoluble fraction was discarded. Protein G beads (Invitrogen) 
were preincubated with anti-NRP1 antibody (Abcam, EPR3113) or 
rabbit IgG (Cell Signaling Technology, 2729) for 30 minutes and then 
mixed with the cell lysates for overnight. Beads were then washed 3 
times with buffer (100 mM NaCl, 50 mM Tris [pH 7.5], 0.1% Triton 
X-100, 5% glycerol). The immunoprecipitates were fractionated by 
4%–12% Bis-Tris-Plus SDS-PAGE gels (Invitrogen) and transferred 
to PVDF membranes. Membranes were blocked for 1 hour with 
Tris-buffered saline with Tween-20 (TBST) containing 5% nonfat dry 
milk. Proteins were detected using mouse monoclonal V5 antibody 
(Invitrogen, R960-25). NRP1 was detected using the same antibody 
for coimmunoprecipitation. After incubation with primary antibodies, 
membranes were washed and incubated with HRP-conjugated anti-
mouse or anti-rabbit secondary antibodies (Cell Signaling Technol-
ogy, 7076, 7074, respectively) followed by detection using ECL sub-
strate (Thermo Fisher Scientific), and exposed using the FluorChem 
M imager (ProteinSimple).
Cloning of allele-specific, mutant GARS–targeted miRNAs
All design rules for artificial miRNAs are previously described (46), 
including: 22-nucleotide mature miRNA length, antisense comple-
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to an extent that made them difficult to distinguish from control mice. 
The primary evaluator of the in vivo mouse studies was also the only 
person proficient at the intrathecal and i.c.v. injections at the time. 
Therefore, although records of which mice were treated or untreated 
were not immediately at hand during the analysis, this information 
was available to the tester.
Neonatal delivery of scAAV9.mi.P278KY and scAAV9.mi.ΔETAQ
Before all injections of mice at P0–P1, all pups were anesthetized via 
cryoanesthesia as previously described (48). Then, all i.c.v. injections 
were performed using a Hamilton syringe (catalog 65460_03) with a 
32-gauge needle and escalating doses of scAAV9.mi.P278KY as stated 
in Supplemental Tables 2 and 3 or 2.6 × 1011 DNAse-1–resistant parti-
cles (DRPS) per mouse of mi.ΔETAQ (about 2–10 μL) diluted in sterile 
PBS. All gene therapy vectors were injected in to the lateral ventricles 
by positioning of the needle directly lateral to the sagittal suture and 
rostral to the neonatal coronal suture. For i.v. injections, all cryoanes-
thetized mice were injected with 1 × 1011 DRPS per mouse directly into 
the superficial temporal vein in a caudal orientation with the use of a 
Hamilton syringe (catalog 7655-01) with a 32-gauge needle.
Intrathecal delivery of gene therapy constructs to post-onset mice
With the use of a Hamilton syringe (catalog 7655-01) with a 32-gauge 
needle, all adult post-onset mice were injected with approximately 1 
× 1011 DRPS per mouse of scAAV9.mi.P278KY or scAAV9.mi.ΔETAQ 
diluted into sterile PBS (~10 μL) via an intrathecal injection by lumbar 
puncture. Here, all mice were anesthetized with isoflurane and received 
an injection of the proper vector into the L6 spinous process with the use 
of a Hamilton syringe with a 32-gauge needle. Each vector was slowly 
injected and the needle left in place for 5–10 seconds before withdrawal.
Quantification of allele-specific expression
Whole liver and lumbar DRG samples were isolated from animals 
immediately after they were euthanized by cervical dislocation. The tis-
sues were frozen in liquid nitrogen and stored at –80°C. Samples were 
homogenized using a mortar and pestle followed by a Dounce homog-
enizer, and RNA was isolated from liver using Trizol Reagent (catalog 
15596018, Thermo Fisher Scientific) and DRGs using either an RNeasy 
Mini Kit (catalog 74104 and 74106, Qiagen) or a mirVana miRNA Isola-
tion Kit (catalog AM1560, Thermo Fisher Scientific). All RNA samples 
were reverse transcribed using SuperScript III First-Strand Synthesis 
System (catalog 18080051). To quantify allele-specific expression of 
WT and mutant GARS, EpigenDx performed pyrosequencing on the 
PSQ96 HS System (Qiagen) following the manufacturer’s instructions, 
using custom assays.
Statistics
Statistical tests were performed using GraphPad Prism 7 software. 
A 2-tailed Student’s t test or 1-way or 2-way ANOVA followed by 
Tukey’s honestly significant difference (HSD) post hoc compar-
isons test (as indicated in the figure legends) was used to deter-
mine significant differences between treatment groups and/or 
genotypes for axon counts, conduction velocity, grip strength, and 
body weight. Axon diameters were compared using nonparametric 
Kolmogorov-Smirnov 2-sample and Shapiro-Wilk normality tests. 
NMJ innervation status between genotypes and categories (fully 
innervated, partially innervated, and denervated) was evaluated 
The ssODN donor sequence was AGTTTACTTGTAACAG-
GCTTTGTTTTATTGGAAGCACATTGTCTTACTTGTAATAGACT-
GGTTTATTTAATTTTATAGATACTTGAGACCGGGGATTTTCtT-
GAATTTCAAACGACTTTTGGAATTCAAC. The sgRNA 144 
sequence was AAAATTCCCTGTGCAGTTTC. The sgRNA 1340 
sequence was TCAGAAATGAGATCTCACCT.
Genotyping. Transgenic mice were genotyped for the presence 
of either the humanized exon 8 or ΔETAQ constructs. Genomic 
DNA was prepared from tail biopsy lysed with proteinase K. Primers 
HuEx8F0_F:CATAACATCACGCGTGGTTCC and HuEx8R0_R:-
CAAGTGTGGCGGTTTCCATC that span the 2.8-kb 5′ arm of homol-
ogy to the 3′ end of Gars exon 8 and subsequent Sanger sequencing 
with HuEx8R0_R were used to identify human single-nucleotide 
polymorphisms in exon 8 of Gars within GarshuEx8 founders and sub-
sequent generations. Primers ΔETAQF0_F:GGCCATAAGCATA-
ATTTTACTGTG and ΔETAQF0_R:TACAACAGAAACAAACT-
GTGGTCA with subsequent Sanger sequencing with ΔETAQF0_R 
were used to detect the 12-bp deletion in bases 13–24 in GarsΔETAQ/+ 
founders and subsequent generations.
Reverse transcriptase PCR. Primers Gars2F_CTCCCACCACTG-
GCAATGAC and Gars2R_CTCACTCAGCAGCAGCTCC were used 
to amplify a portion of the Gars open reading frame spanning Gars 
exon 8 from first-strand cDNA generated from sciatic nerve RNA iso-
lated from Gars+/huEx8 and GarsΔETAQ/huEx8 mice. Humanized exon 8 and 
ΔETAQ transcript sequences were identified with Sanger sequencing 
and primer Gars2F.
Tissue lysate preparation. Whole brain samples were isolated 
from animals immediately after they were euthanized by CO2 inha-
lation. The tissues were frozen in liquid nitrogen and stored at –80°C. 
Samples were homogenized using a mortar and pestle followed by a 
Dounce homogenizer in 1% NP-40 in PBS supplemented with Prote-
ase Inhibitor Cocktail Tablets (Roche), then centrifuged at 14,000 g 
twice for 5 minutes at 4°C. Cleared homogenates were then sonicated 
at 4°C and centrifuged again at 14,000 g for 5 minutes. Twenty micro-
grams of protein was then analyzed by immunoblot.
Western blot analysis. Protein lysates were resolved on Mini- 
PROTEAN 4%–15% Tris-glycine gels (Bio-Rad) and transferred to 
an Invitrolon & Immobilon-P PVDF membrane for Western blot 
analysis. Membranes were blocked with 5% skim milk in TBST (1× 
Tris-buffered saline, 0.1% Tween-20), and incubated overnight with 
anti-GARS (rabbit; Abcam, ab42905; 1:1000 dilution) and anti-NeuN 
(mouse monoclonal; Cell Signaling Technology, E4M5P; 1:1000) 
diluted in blocking solution at 4°C. After three 10-minute washes in 
TBST, the blots were incubated with the appropriate HRP-conjugated 
secondary antibodies (PerkinElmer, NEF812, NEF822001EA) diluted 
in blocking solution. After three 10-minute washes in TBST, the blots 
were developed using Western Lightening Plus-ECL, Enhanced Che-
miluminescence Substrate (PerkinElmer).
Assessment of axonal neuropathy in all mouse models
Grip strength was evaluated by wire hang test (20, 26) to evaluate 
gross muscle strength and endurance. Nerve conduction studies, 
motor nerve histology and analysis, NMJ immunofluorescence and 
analysis, and body weight evaluation were completed as previously 
described (20, 30). These studies were not formally blinded. First, the 
Gars mice have a visible phenotype that makes blinding with respect to 
genotype difficult, although mice treated at birth were often rescued 
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with a 2-way ANOVA followed by Tukey’s HSD post hoc compari-
sons test. A P value less than 0.05 was considered significant.
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